Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CMNDBullishCorporate Developmentsnews

High materiality8/10

Clearmind Advances CMND-100 to Phase IIa for Alcohol Use Disorder

Sep 1, 2026, 7:39 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive trial progression, DSMB endorsement, and patient enrollment at two sites are concrete, time-bound catalysts likely to trigger a price uptick in the near term, albeit with biotech risk and data-dependent outcomes.

AI summary

What happened, with direct paths to the underlying reporting

Clearmind Medicine announced that CMND-100 has progressed into Phase IIa of its Phase I/IIa AUD study, enrolling six patients across Tel Aviv and Jerusalem. A DSMB review endorsed advancing beyond Part A, enabling multiple dosing in volunteers and single dosing in AUD patients, signaling potential data readouts and valuation catalysts over the next 6–12 months.

CMND-100 enters Phase IIa for AUD; six patients enrolled (3 TASMC, 3 Hadassah).
DSMB recommends advancing after Part A; enables multi-dose in volunteers and single-dose in patients.
Phase I/IIa is four-part; evaluates safety, tolerability, PK in volunteers and AUD patients.
CMND: lead psychedelic-based candidate; portfolio includes 19 patent families and 32 granted patents.
AUD remains a global health burden with limited effective treatments.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Clearmind Advances CMND-100 to Phase IIa for Alcohol Use Disorder

DSMB approves CMND-100 advancement to AUD patient cohorts, signaling clinical progress

Clearmind Medicine Achieves Key Milestone for Alcohol Use Disorder Treatment